drugset / Trial / NCT04967950
An Efficacy Study of Secukinumab In Enthesitis of Psoriatic Arthritis Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
Given the role of IL-17 in the development of entheseal-driven pathology, a therapeutic strategy aimed at blocking IL-17 would be a logical option for the treatment of enthesitis in psoriatic arthritis patients. This study will be the first randomized trial of a biologic therapy in participants with psoriatic arthritis, using imaging test.
Timeline
- Start
- 2021-07-15
- Primary completion
- 2022-10-31
- Completion
- 2022-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Methotrexate | Small molecule | 15 mg | Oral |
| Subject | Secukinumab | Monoclonal antibody | 150 mg | Subcutaneous |
| Subject | Secukinumab | Monoclonal antibody | 300 mg | Subcutaneous |